Jazz Pharmaceuticals financials
$232.35−2.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.21B | $1.07B | $1.20B | $1.13B | $1.05B | $897.8M | $1.09B | $1.05B | $1.02B | $902.0M | $1.01B | $972.1M |
| Gross profit | $1.09B | $934.8M | $1.04B | $997.2M | $929.4M | $793.2M | $959.5M | $943.4M | $913.9M | $806.5M | $904.7M | $870.0M |
| Gross margin | 90.4% | 87.5% | 87.2% | 88.6% | 88.9% | 88.3% | 88.2% | 89.4% | 89.3% | 89.4% | 89.4% | 89.5% |
| Operating income | $248.2M | $213.8M | $254.5M | $57.5M | -$686.4M | -$55.9M | $190.8M | $260.2M | $199.4M | $66.2M | $122.5M | $172.4M |
| Net income | $192.8M | $293.1M | $203.5M | $251.4M | -$718.5M | -$92.5M | $191.1M | $215.1M | $168.6M | -$14.6M | $94.2M | $146.8M |
| Net margin | 16.0% | 27.4% | 17.0% | 22.3% | −68.7% | −10.3% | 17.6% | 20.4% | 16.5% | −1.6% | 9.3% | 15.1% |
| Diluted EPS | $2.78 | $4.43 | $3.38 | $4.08 | $-11.74 | $-1.52 | $2.78 | $3.42 | $2.49 | $-0.23 | $1.35 | $2.14 |
| EBITDA | $504.3M | $395.2M | $433.7M | $278.3M | $393.0M | $108.9M | $359.2M | $425.4M | $362.5M | $239.6M | $140.5M | $334.9M |
| Operating cash flow | $415.7M | $408.2M | $362.5M | $474.6M | $88.8M | $429.8M | $398.6M | $398.7M | $331.4M | $267.2M | $167.3M | $307.2M |
| Free cash flow | $397.6M | $311.3M | $345.8M | $459.4M | $75.9M | $415.9M | $385.3M | $388.0M | $324.3M | $260.3M | $139.2M | $302.9M |
| Diluted shares | 69.4M | 66.1M | 60.1M | 61.6M | 61.2M | 61.0M | 68.7M | 63.2M | 69.6M | 62.5M | 69.7M | 71.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.62B | $1.84B | $1.39B | $1.33B | $1.19B | $1.86B |
| Short-term investments | $580.0M | $1.03B | $1.05B | $720.0M | $480.0M | $710.0M |
| Total debt | $4.35B | $5.35B | $5.36B | $5.36B | $5.36B | $5.37B |
| Total assets | $11.08B | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B |
| Total liabilities | $6.28B | $7.33B | $7.34B | $7.40B | $7.24B | $7.36B |
| Shareholders' equity | $4.80B | $4.53B | $4.32B | $3.96B | $3.71B | $4.17B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology